Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

Halozyme Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on innovative drug delivery technologies, has elected Jim (James) Lang to its Board of Directors.5 6

Halozyme announced the election of James Lang to its board on December 4, 2025, with a term running until the company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified.6

A subsequent release on December 17, 2025 from Bench International, the executive search firm that led the recruitment, highlighted Lang’s appointment and framed it as strengthening Halozyme’s board as the company advances its global drug delivery platform.1 2 7

Jim Lang brings extensive experience in scaling life sciences organizations and providing governance oversight for public companies in complex, highly regulated environments.1 2

He currently serves on the public boards of OptimizeRx Corp. and BioVie Inc., adding additional healthcare and life sciences board experience to Halozyme.1 2

Bench International characterized Lang as having a rare combination of public-company board experience, strategic scale expertise, and a deep understanding of complex life sciences ecosystems.1 2

Halozyme’s Nominating and Governance Committee, through its chair Matthew L. Posard, emphasized that Lang met the company’s high standards for board members and that the appointment reflects Halozyme’s focus on strong corporate governance and board leadership.1 2

Investor-focused commentary has linked Lang’s appointment with a broader positive shift in Halozyme’s investment narrative, especially when considered alongside a recent patent win, suggesting potential implications for valuation and risk profile.3 4

Analyst and market commentary describe Lang as a seasoned dealmaker, with expectations that his presence on the board could support Halozyme’s strategic partnerships, global collaborations, and potential business development activities.3 4

The overall framing of the news is that Jim Lang’s arrival is intended to support Halozyme’s next phase of growth, particularly around its global drug delivery platform and partnerships with leading pharmaceutical companies.1 2 4